- This chapter outlines how to structure an effective strength training program for building muscle mass, including workout splits, exercise selection, and training techniques
- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Every year, innovators rush into GLP studies before they're truly ready
Who Should Choose TrimRx TrimRx makes the most sense for patients who want a single, predictable monthly price without a separate membership fee
Steven Klein, a physician at the nonprofit Caron Treatment Centers in Providence
Let's be honest about what actually works, what doesn't, and what might put your health at risk
Six observational studies have evaluated pregnancy outcomes after exposure to GLP-1 receptor agonists (GLP-1 RAs)
